Fig. 3

HIV-specific CTL responses in progressor R097 and in non-progressor RI088. EliSpot assays tested recognition of overlapping 18mer peptides, which together spanned the B clade proteome. The figure includes the full sequence of each 18mer peptide recognised and the HLA restriction where known, with known optimal epitopes shown in bold. a EliSpot responses detected in progressor R097 at time 0 (diagnosis) and 2.0 years later. Data shown at 2.0 years are the median of 3 assays undertaken at 1.96, 1.98 and 2.15 years after time 0. No responses were detected to the 18mer peptides containing the epitopes ISPRTLNAW or STTVKAACWW at either timepoint. b Responses detected in non-progressor RI088 at the times shown post diagnosis. Selected peptides that were strongly recognized in R097 but not in RI088 are included in panel B